Welcome to our dedicated page for Kiniksa Pharmaceuticals International, plc SEC filings (Ticker: KNSA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Kiniksa Pharmaceuticals International, plc filings document regulatory disclosures for a Nasdaq-listed biopharmaceutical company incorporated in England and Wales. Form 8-K reports cover operating results and financial condition, ARCALYST portfolio execution, investor presentations, and executive appointments or consulting arrangements.
Proxy materials cover annual meeting matters, director elections, executive compensation, shareholder voting procedures, and board governance. The filing record also identifies the company’s Class A ordinary shares, Nasdaq Global Select Market listing, and recurring disclosures tied to its commercial ARCALYST franchise and cardiovascular-focused development portfolio.
Kiniksa Pharmaceuticals (KNSA) officer Michael R. Megna reported changes in beneficial ownership on 10/04/2025. The filing shows 175 restricted share units (RSUs) granted (transaction code M) that convert into Class A ordinary shares and vest over four years with 25% vesting each anniversary of the grant date of 10/04/2021. The reporting person also recorded a sale of 85 Class A ordinary shares (transaction code F) at $38.49, leaving 38,101 shares owned after the sale. Following the RSU grant, total beneficial ownership is reported as 38,186 shares. The form was signed by an attorney-in-fact on 10/08/2025.
Tessari Eben, Chief Operating Officer of Kiniksa Pharmaceuticals International plc (KNSA), exercised 42,000 previously granted options at an exercise price of $17.92 on 09/29/2025, acquiring 42,000 Class A ordinary shares. The option is fully vested and exercisable and has an expiration date of 03/03/2029.
The reporting person sold 42,000 Class A ordinary shares the same day under a 10b5-1 trading plan established April 29, 2024, at a weighted-average sales price of $38.33 per share (trades ranged $37.92–$38.85). After these transactions the reporting person beneficially owned 34,552 Class A ordinary shares.
Kiniksa Pharmaceuticals International, plc (KNSA) filing a Form 144 notifies the intended sale of 42,000 Class A ordinary shares on 09/29/2025 through Charles Schwab & Co., Inc. The shares were acquired the same day via an employee stock option exercise and will be sold in a broker-assisted cashless exercise, with the filing reporting an aggregate market value of $1,609,716 against ~43.47 million shares outstanding.
The filing also discloses prior sales by the same holder, Eben Tessari, totaling 303,865 shares sold across seven transactions from 07/14/2025 to 09/15/2025 for aggregate gross proceeds shown per trade. The notice is a required disclosure under Rule 144 and includes the signer’s representation there is no undisclosed material information.
Kiniksa Pharmaceuticals (KNSA) Form 4 — transactions by Eben Tessari. The filing shows transactions on 09/15/2025 executed under a 10b5-1 plan established April 29, 2024. Tessari acquired 6,500 Class A ordinary shares by exercise of options at an $8.83 exercise price and reported ownership of 6,500 underlying shares from that option. On the same date Tessari sold 16,044 Class A shares at a weighted average price of $36.45 and sold 356 Class A shares at a weighted average price of $37. After these transactions reported beneficial ownership counts include 50,952, 34,908, and 34,552 shares respectively. The option involved is described as fully vested and exercisable.
Kiniksa Pharmaceuticals (KNSA) Form 4 — transactions by Eben Tessari. The filing shows transactions on 09/15/2025 executed under a 10b5-1 plan established April 29, 2024. Tessari acquired 6,500 Class A ordinary shares by exercise of options at an $8.83 exercise price and reported ownership of 6,500 underlying shares from that option. On the same date Tessari sold 16,044 Class A shares at a weighted average price of $36.45 and sold 356 Class A shares at a weighted average price of $37. After these transactions reported beneficial ownership counts include 50,952, 34,908, and 34,552 shares respectively. The option involved is described as fully vested and exercisable.
Tessari Eben, Chief Operating Officer and director of Kiniksa Pharmaceuticals International, plc (KNSA), reported exercises of vested share options and subsequent sales on September 4 and 5, 2025 under a 10b5-1 plan. The reporting person exercised a total of 98,660 share options at exercise prices of $15.50 and $15.52, resulting in the acquisition of 98,660 Class A Ordinary Shares. That same week the reporting person sold 98,660 Class A Ordinary Shares in multiple brokered trades at weighted-average prices of about $35.52 and $35.66. After these transactions the reporting person beneficially owned 44,452 Class A Ordinary Shares. The 10b5-1 plan was executed on April 29, 2024, and the Form 4 was signed by an attorney-in-fact on September 8, 2025.
Kiniksa Pharmaceuticals (KNSA) insider sale: Ross Moat, Chief Corporate & Commercial Officer and director, reported a disposition of 3,523 Class A ordinary shares on 09/04/2025 at a price of $35.31 per share. Following the sale, Mr. Moat beneficially owned 9,415 Class A ordinary shares directly. The filing notes the sale was executed pursuant to a 10b5-1 trading plan adopted on November 13, 2024. The Form 4 was signed by an attorney-in-fact on 09/08/2025.
Kiniksa Pharmaceuticals International, plc (KNSA) Form 144 notice reports a proposed sale of 13,389 Class A ordinary shares through Charles Schwab & Co., Inc. on 09/05/2025, with an aggregate market value of $477,497.00. The shares were acquired the same day by employee stock option exercise and the payment method is listed as broker payment for cashless exercise. The filing lists multiple prior sales by the same seller, Eben Tessari, between 06/09/2025 and 09/04/2025, including several larger transactions reported on 06/11/2025, 08/05/2025 and 09/04/2025. Outstanding shares are shown as 43,472,928.
Kiniksa Pharmaceuticals International, plc (KNSA) filed a Form 144 notifying a proposed sale of 85,271 Class A ordinary shares through Charles Schwab & Co., Inc. with an aggregate market value of $3,028,740, approximately to be sold on 09/04/2025 on NASDAQ. The shares were acquired the same day via an employee stock option exercise and were settled by a broker payment for a cashless exercise.
The filing also lists insider sales over the past three months by Eben Tessari totaling 381,932 shares across multiple dates with combined gross proceeds of $7,482,197.
Kiniksa Pharmaceuticals International, plc (KNSA) reported a Form 144 notice for a proposed sale of 3,523 Class A ordinary shares through Charles Schwab & Co., with an aggregate market value of $124,397. The filing shows the shares were acquired by restricted stock lapse as equity compensation on 09/01/2025 (3,010 shares) and 09/02/2025 (513 shares). The company’s total outstanding Class A shares are listed as 43,472,928, and the sale is scheduled approximately for 09/04/2025. The notice contains the standard attestations about absence of undisclosed material information and compliance with Rule 144 and Rule 10b5-1 disclosures.
Kiniksa Pharmaceuticals (KNSA) Form 4 — Tessari Eben, Chief Operating Officer. The filing shows multiple equity awards and transactions between September 1–3, 2025. RSUs were granted/recorded totaling 9,828 RSUs on 09/01/2025 and additional RSUs from prior grants are reflected; each RSU converts to one Class A ordinary share. New stock options were granted on 09/01/2025 for 39,364 shares at a $33.49 exercise price and earlier vested options and RSUs remain outstanding. The reporting person sold 15,091 Class A shares on 09/03/2025 at a weighted average price of $35.50 and recorded additional small open-market sales on 09/01–09/02 at $33.49 and $34.28. Post-transactions beneficial ownership totals are reported in the range of 43,438 to 59,543 Class A shares depending on line items.